本文選題：戶塵螨　切入點(diǎn)：特異性免疫治療　出處：《中國寄生蟲學(xué)與寄生蟲病雜志》2017年01期 　論文類型：期刊論文

【摘要】：目的通過戶塵螨(Dermatophagoides pteronyssinus)2類變應(yīng)原Der p 2 T細(xì)胞表位融合肽對哮喘小鼠的特異性免疫治療,探討信號轉(zhuǎn)導(dǎo)因子和轉(zhuǎn)錄活化因子6(signal transducer and activator of transcription factor 6,STAT6)的變化及其特異性免疫治療的作用機(jī)制。方法 30只小鼠用隨機(jī)數(shù)表法分為哮喘組、Der p 2 T細(xì)胞表位融合肽免疫治療組(簡稱免疫治療組)和陰性對照組(PBS組),每組10只。哮喘組和免疫治療組分別于第0、7、14天經(jīng)小鼠腹腔注射100μl致敏液[含100μg/ml Der p2和2%Al(OH)3的PBS液],PBS組注射等量PBS液[含2%Al(OH)3]。哮喘組和免疫治療組自第21天起,霧化吸入0.5μg/ml Der p 2致敏液,1次/d×30 min,連續(xù)7 d;PBS組霧化吸入等量PBS液。免疫治療組在第25~27天霧化前30 min,經(jīng)腹腔注射100μg/ml Der p 2 T細(xì)胞表位融合肽200μl,PBS組和哮喘組注射等量PBS液。末次霧化吸入24 h后處死小鼠,收集每組小鼠的支氣管肺泡灌洗液(BALF),用ELISA檢測BALF中白細(xì)胞介素-4(IL-4)、IL-13、γ干擾素(IFN-γ)水平。取肺組織提取肺組織全蛋白,蛋白質(zhì)印記(Western blotting)檢測肺組織全蛋白中STAT6和磷酸化STAT6(p-STAT6)的表達(dá)情況。組間樣本的均數(shù)比較采用單因素方差分析。結(jié)果免疫治療組小鼠的IFN-γ水平為(234.40±24.46)pg/ml,高于哮喘組的(155.80±20.53)pg/ml(P0.01);免疫治療組小鼠的IL-4和IL-13水平分別為(30.00±5.50)和(174.50±25.99)pg/ml,均低于哮喘組小鼠的(53.28±8.26)和(308.10±28.32)pg/ml(P0.01)。免疫治療組小鼠STAT6、p-STAT6的相對表達(dá)量分別為0.803±0.221和0.966±0.323,均低于哮喘組的1.669±0.296和1.735±0.298(P0.01)。結(jié)論 Der p 2 T細(xì)胞表位融合肽可能通過抑制STAT6治療哮喘組小鼠。
[Abstract]:Objective to study the specific immunotherapy of asthmatic mice with Dermatophagoides pteronyssinus)2 Der p2 T cell epitope fusion peptide. To investigate the changes of signal transducer and activator of transcription factor 6T 6 and the mechanism of specific immunotherapy. Methods Thirty mice were randomly divided into asthmatic group with Der p2 T cell epitope fusion peptide. There were 10 rats in each group in immunotherapy group and 10 in negative control group. The asthmatic group and immunotherapy group were injected 100 渭 l sensitized solution [100 渭 g / ml Der p2 and 2AlOHN3 PBS solution] by intraperitoneal injection on the 7th and 14th day, respectively, in the asthmatic group and the immunotherapy group. PBS solution [2] .Asthma group and immunotherapy group from the 21st day, 0. 5 渭 g / ml Der p2 sensitizer was inhaled once per day for 30 minutes, and the same amount of PBS was inhaled continuously for 7 days. In the immunotherapy group, 100 渭 g / ml Der p2 T cell epitope fusion peptide was injected intraperitoneally 30 minutes before atomization on the 25th day, and the same amount was injected into the asthma group and 100 渭 g / ml Der p2 T cell epitope fusion peptide. The mice were killed 24 hours after the last inhalation of PBS solution. The bronchoalveolar lavage fluid (BALFN) was collected from each group of mice. The levels of IL-4, IL-4, IL-13, IFN- 緯 in BALF were detected by ELISA. The expression of STAT6 and phosphorylated STAT6 p-STAT6) in lung tissue was detected by Western blotting. The results showed that the level of IFN- 緯 in immunotherapy group was 234.40 鹵24.46 渭 g / ml, higher than that in asthma group (155.80 鹵20.53pgml-1). The levels of IL-4 and IL-13 in the immunotherapy group were 30.00 鹵5.50) and 174.50 鹵25.99pg / ml respectively, which were lower than those in the asthmatic group (53.28 鹵8.26) and 308.10 鹵28.32pg / ml / ml respectively. The relative expressions of STAT6p-STAT6 in immunotherapy group were 0.803 鹵0.221 and 0.966 鹵0.323respectively, which were lower than those in asthmatic group (1.669 鹵0.296 and 1.735 鹵0.298p 0.01g / ml). Conclusion the relative expression of STAT6p-STAT6 in immunotherapy group is 0.803 鹵0.221 and 0.966 鹵0.3233.Conclusion the relative expression of STAT6p-STAT6 in immunotherapy group is 0.803 鹵0.221 and 0.966 鹵0.323, which is lower than that in asthma group. The fusion peptide may inhibit the treatment of asthmatic mice by inhibiting STAT6.
【作者單位】： 皖南醫(yī)學(xué)院活性生物大分子研究安徽省重點(diǎn)實(shí)驗(yàn)室;安徽師范大學(xué)生命科學(xué)學(xué)院;
【基金】：國家自然科學(xué)基金(No.81270091,30872367) 安徽省高校自然科學(xué)研究重點(diǎn)項(xiàng)目(No.KJ2016A736) 安徽省自然科學(xué)基金(No.070413088)~~
【分類號】：R562.25

【相似文獻(xiàn)】

相關(guān)期刊論文 前7條

1 王成陽;李澤庚;劉向國;彭青和;武松;張凱;呂磊;;六味補(bǔ)氣膠囊對COPD肺氣虛證模型STAT4,STAT6蛋白表達(dá)影響[J];中國實(shí)驗(yàn)方劑學(xué)雜志;2013年21期

2 徐雪梅;符州;田代印;劉恩梅;王莉佳;黃英;;小鼠STAT4、STAT6基因克隆及其真核表達(dá)質(zhì)粒的構(gòu)建[J];重慶醫(yī)科大學(xué)學(xué)報(bào);2008年08期

3 胡俊華,吳健民,崔天盆,李一榮;STAT6基因3′非翻譯區(qū)G2964A位點(diǎn)多態(tài)性與湖北漢族哮喘人群及IgE的相關(guān)性研究[J];臨床檢驗(yàn)雜志;2005年01期

4 楊琴;符州;田代印;劉恩梅;王莉佳;黃英;;小鼠STAT4,STAT6基因shRNA真核表達(dá)質(zhì)粒的構(gòu)建及鑒定[J];重慶醫(yī)科大學(xué)學(xué)報(bào);2009年01期

5 鄒麗萍;張希;張艷;許秀娟;王鐵鋒;;STAT6和ORMDL3在哮喘小鼠肺組織中的表達(dá)及布地奈德的干預(yù)作用[J];中國當(dāng)代兒科雜志;2014年02期

6 王玉梅;羅元平;羅莉;;STAT5、STAT6在哮喘肺組織的表達(dá)[J];中國臨床研究;2011年11期

7 ;[J];;年期

相關(guān)會議論文 前1條

1 楊學(xué)敏;史海廣;成家軍;宋立強(qiáng);李志奎;;聯(lián)合應(yīng)用sIL-5Ra及sIL-13Ra2對哮喘小鼠VCAM-1、STAT6水平的影響[A];第六次全國中西醫(yī)結(jié)合變態(tài)反應(yīng)學(xué)術(shù)大會論文匯編[C];2013年

相關(guān)碩士學(xué)位論文 前1條

1 段彬彬;STAT6信號通路在Der p2的T細(xì)胞表位融合肽特異性免疫治療中的機(jī)制探討[D];皖南醫(yī)學(xué)院;2016年

，

本文編號：1588750